Topical Eye Drop Composition for Mustard Gas Corneal Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are inadequate for effectively treating chemically induced corneal damage, particularly from sulfur mustard gas exposure, which causes severe corneal injury, inflammation, and irreversible blindness, with no easy-to-administer options that do not have off-target effects.
Innovation Solution
A pharmaceutical composition comprising a nonsteroidal anti-inflammatory drug (NSAID), a histone deacetylase (HDAC) inhibitor, and an angiotensin converting enzyme (ACE) inhibitor, formulated as a topical ophthalmic solution to mitigate both acute and delayed toxicity from mustard gas exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current therapies are used to treat chemically induced corneal damage, then treatment is provided, but they are not easy to administer and have off-target effects
Solution Approach 1:
The patent combines multiple therapeutic agents (corticosteroid, NSAID, and antibiotic) into a single ophthalmic composition. This merging approach allows the formulation to address multiple pathological mechanisms simultaneously while maintaining ease of administration through a single dosage form, thereby resolving the contradiction between ease of use and comprehensive effective treatment.
2Ease of operation
If a single therapy is used, then administration is simple, but it cannot effectively treat both acute and delayed toxicity
Solution Approach 1:
The composition integrates three distinct therapeutic agents that target different phases and mechanisms of mustard gas toxicity. The corticosteroid addresses acute inflammation, the NSAID provides anti-inflammatory and analgesic effects, and the antibiotic prevents secondary infections. This combination enables a single administration regimen to effectively treat both acute and delayed toxicity manifestations.
Solution Approach 2:
The ophthalmic composition is designed with multi-functional capabilities to address diverse pathological processes including inflammation, pain, and infection risk. This universal formulation can be applied to various stages of corneal damage from acute exposure, making it adaptable to both immediate and delayed treatment needs while maintaining simple administration.
3Reliability
If multiple separate treatments are used to address different mechanisms, then comprehensive treatment is provided, but administration becomes complex
Solution Approach 1:
The patent merges multiple separate therapeutic agents into a single integrated ophthalmic composition. This eliminates the need for patients to administer multiple separate treatments, thereby reducing regimen complexity while maintaining comprehensive treatment effectiveness against acute and delayed toxicity through synergistic action of the combined agents.
Data Source
AI summary
Provided herein are compositions suitable for treating chemically induced eye damage comprising (a) a nonsteroidal anti-inflammatory drug (NSAID), (b) a histone deacetylase (HDAC) inhibitor and (c) an angiotensin converting enzyme (ACE) inhibitor and, optionally, (d) a water-soluble vitamin. Methods of using provided compositions to treat ocular toxicity and corneal damage following exposure to chemical agents (e.g., mustard gas) are also provided.